|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100046956 |
|
最近更新日期: Date of Last Refreshed on: |
2022-01-12 18:56:08 |
|
注册时间: Date of Registration: |
2021-06-02 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
黄连素对人群高胆碱饮食后肠道菌群及其代谢产物和心血管功能的影响 |
|
Public title: |
Effects of Berberine on Intestinal Microflora, Metabolites and Cardiovascular Function in People After High Choline Diet |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
黄连素对人群高胆碱饮食后肠道菌群及其代谢产物和心血管功能的影响 |
|
Scientific title: |
Effects of Berberine on Intestinal Microflora, Metabolites and Cardiovascular Function in People After High Choline Diet |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邵奕嘉 |
研究负责人: |
邵奕嘉 |
|
Applicant: |
Shao Yijia |
Study leader: |
Shao Yijia |
|
申请注册联系人电话: Applicant telephone: |
+86 13826161782 |
研究负责人电话: Study leader's telephone: |
+86 13826161782 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shaoyj3@mail2.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
shaoyj3@mail2.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市越秀区中山二路58号 |
研究负责人通讯地址: |
广州市越秀区中山二路58号 |
|
Applicant address: |
58 Second Zhongshan Road, Yuexiu District, Guangzhou, Guangdong, China |
Study leader's address: |
58 Second Zhongshan Road, Yuexiu District, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Sun Yat-Sen University |
||
|
研究负责人所在单位: |
中山大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Sun Yat-Sen University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020-59601 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州市妇女儿童医疗伦理委员会 |
||
|
Name of the ethic committee: |
Guangzhou Women and Children Medical Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-04-04 00:00:00 |
||
|
伦理委员会联系人: |
李庆丰 |
||
|
Contact Name of the ethic committee: |
Li Qingfeng |
||
|
伦理委员会联系地址: |
广州市天河区金穗路9号 |
||
|
Contact Address of the ethic committee: |
9 Jinsui Road, Tianhe District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Sun Yat-Sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市越秀区中山二路58号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
58 Second Zhongshan Road, Yuexiu District, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
Target disease: |
N/A |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
明确黄连素在高胆碱饮食人群中降低TMAO水平以及改善血管内皮功能的作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
To determine the role of berberine in reducing TMAO levels and improving vascular endothelial function in people with high choline diet. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.男性,18岁~45岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Male, aged between 18 and 45 years; |
||||||||||||||||||||||
|
排除标准: |
符合以下任一标准的受试者均将从本试验中排除: |
||||||||||||||||||||||
|
Exclusion criteria: |
Subjects meeting any of the following criteria will be excluded from the study: |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-01-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
所有受试者签署知情同意书后,通过随机序列以1:1:1比例将受试者随机分配至空白对照组、高胆碱(鸡蛋)干预组、高胆碱(鸡蛋)+黄连素干预组。受试者获得随机序列号,并将分配信息隐藏在密封的信封里,研究者(相关检查检验人员、数据统计分析人员)不清楚分配入组信息。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After all subjects signed the informed consent form, they were randomly assigned to the blank control group, the high choline (egg) intervention group, and the high choline (egg) + berberine intervention group in a 1:1:1 ratio through a random sequence.Subjects were given random serial numbers, and the assignme |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
研究者(相关检查检验人员、数据统计分析人员)不清楚分配入组信息。 |
|
Blinding: |
The researchers (related inspection inspectors, statistical analysis personnel) did not know the assignment information. |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2022年发表文章 请阅读网页注册指南中关于 原始数据共享 的内容。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not stated |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表,电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record form and electronic data capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |